GlassScriptPhysician profile
John P Geisler
NPI 1437146081
$546.96
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $102.17 | 2019 | |
| Puma Biotechnology, INC. | $81.21 | 2019 | |
| Clovis Oncology, INC. | $76.17 | 2019 | |
| Tesaro, INC. | $70.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.12 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $35.50 | 2019 | |
| Lilly USA, LLC | $35.27 | 2019 | |
| Merck Sharp & Dohme LLC | $31.30 | 2019 | |
| Celgene Corporation | $28.19 | 2019 | |
| Janssen Biotech, INC. | $14.97 | 2019 | |
| Kyowa Kirin, INC. | $14.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Geisler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.